Institute Research

Introduction

The Institute is a non-profit organisation committed to researching radiowave therapy for the treatment of cancer, within the following broad objectives:

  • To sponsor radiowave therapy research projects in Australia and overseas, wherever access to best practice technologies, facilities, resources and know-how exist.
  • To undertake sequential independent research projects, the outcomes of which will inherently reinforce the findings of each other, at the same time act to define the extent of subsequent research projects. In the process of testing a broad range of hypotheses in relation to radiowave therapy, to ensure that the aim of random clinical trails remains the foremost expeditious end point.
  • To put radiowave therapy into context with conventional cancer treatments – this could be as an adjuvant or neoadjuvant therapy or in some other stand alone capacity.

The Institute first funded pilot in vitro research projects with the Dublin Institute of Technology and the Institute of Technology Sligo (IT Sligo) in Ireland.

The pilot project outcomes were encouraging and the Institute founders are proceeding to fund the next stages of research, commenced July 2013, with key end points expected by June 2016.

A number of research organisations are advising, involved with and/or carrying out the radiowave therapy cancer research and include: IT Sligo; Charles River Laboratories (CRL); Johns Hopkins School of Medicine; Curtin University; Radiowave Therapy Clinic; and Dublin Institute of Technology.

IT Sligo is in effect the hub for research co-evaluation in Ireland where excellent independent facilities are provided to conduct in vitro and in vivo research.

Once the protocols for in vivo studies with rat models are finalised, Johns Hopkins can recommence studies with certain brain cancer lines. This is expected to commence again in 2014.

The Institute will, over the next 3 years (to 2016), be studying radiowave treatment of 10 common cancer types in vitro and in vivo through IT Sligo and CRL.

The Radiowave Therapy Clinic is documenting case studies.

Curtin University is providing cell lines and have mouse models for specific studies in Australia and overseas.

The Institute has not published research outcomes to date because projects have been pilot studies, privately commissioned to justify the significant radiowave treatment now being undertaken by the Institute and the Radiowave Therapy Clinic.

Further, it is an Institute Board mandate that publishing results will not happen until there is a significant body of evidence, through independent research, to satisfy or otherwise the medical community of the efficacy of the treatment, in the pursuit of undertaking clinical trials.